A Phase 2, Open Label Single Arm Study for Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2018
At a glance
- Drugs Apremilast (Primary)
- Indications Dermatomyositis
- Focus Therapeutic Use
- 13 Jun 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Dec 2018.
- 13 Jun 2018 Status changed from not yet recruiting to recruiting.
- 23 May 2018 New trial record